Department of Internal Medicine, School of Medicine, Kyungpook National University and Kyungpook National University Hospital, Daegu, Korea.
Gut Liver. 2022 Jan 15;16(1):37-43. doi: 10.5009/gnl20298.
BACKGROUND/AIMS: After esophagogastroduodenoscopy (EGD) with biopsy, some patients experience gastrointestinal symptoms. This study investigated the effect of sodium alginate on biopsy-related gastrointestinal symptoms.
In this open-label, randomized, controlled trial, patients undergoing EGD with biopsy were randomly assigned to a treatment or control group. In the treatment group, sodium alginate was orally administered for 3 days after EGD. Patients completed questionnaires about their gastrointestinal symptoms at baseline (past week), the day after returning home, and after another 3 days. Gastrointestinal symptoms, including abdominal pain, epigastric pain/soreness, heartburn, acid reflux, nausea/vomiting, borborygmus, abdominal distension, and belching, were rated using an upper gastrointestinal symptom rating scale (GSRS).
A total of 210 persons (138 men) who underwent EGD with biopsy were enrolled and allocated to the treatment (n=104) or control (n=106) group. At baseline, the demographic factors and GSRS scores were not different between the control and treatment groups. The epigastric pain/soreness score increased in the control group after endoscopic biopsy (+0.056), whereas the score was decreased in the treatment group (-0.067) (p=0.042). In the treatment group, the scores for acid regurgitation and epigastric soreness decreased during follow-up from those at baseline (p<0.05), whereas there were no significant reductions in the control group. The scores for belching and borborygmus decreased during follow-up only in the treatment group. Abdominal bloating decreased in both the control and treatment groups.
Sodium alginate reduced epigastric pain/soreness after EGD with biopsy. Therefore, the prescription of sodium alginate should be considered after endoscopic biopsy.
背景/目的：在进行食管胃十二指肠镜检查（EGD）并进行活检后，一些患者会出现胃肠道症状。本研究旨在探讨海藻酸钠对活检相关胃肠道症状的影响。
这是一项开放标签、随机、对照临床试验，接受 EGD 并进行活检的患者被随机分配至治疗组或对照组。在治疗组中，患者在 EGD 后口服海藻酸钠 3 天。患者在基线（过去一周）、回家后第 1 天和第 4 天完成胃肠道症状问卷。采用上消化道症状评分量表（GSRS）评估腹痛、上腹痛/不适、烧心、反酸、恶心/呕吐、肠鸣、腹胀和呃逆等胃肠道症状。
共有 210 名（男 138 名）接受 EGD 并进行活检的患者入组并被分配至治疗组（n=104）或对照组（n=106）。基线时，对照组和治疗组的人口统计学因素和 GSRS 评分无差异。与对照组相比，治疗组内镜活检后上腹痛/不适评分增加（+0.056），而治疗组评分降低（-0.067）（p=0.042）。在治疗组中，酸反流和上腹痛的评分在随访期间从基线开始下降（p<0.05），而对照组无明显下降。仅在治疗组中，呃逆和肠鸣的评分在随访期间下降。对照组和治疗组的腹胀均减少。
海藻酸钠可减轻 EGD 并进行活检后的上腹痛/不适。因此，内镜活检后应考虑开具海藻酸钠处方。
